Prostate Cancer Reports

Volume 1 Supplement 7
 July 2013
Home > Prostate Cancer Reports > Volume 1 - Year 2013 > Supplement 7, July 2013


Localized PCa
Locally advanced PCa


American Urological Association

Bott SR, Birtle AJ, Taylor CJ, Kirby RS.
Prostate cancer management: (1) an update on localised disease.
Postgrad Med J. 2003 Oct;79(936):575-80
Abstract | Full text | Related citations

Bott SR, Birtle AJ, Taylor CJ, Kirby RS.
Prostate cancer management: 2. An update on locally advanced and metastatic disease.
Postgrad Med J. 2003 Nov;79(937):643-5.
Abstract | Full text | Related citations



Schroeck FR, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Freedland SJ.
Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?
BJU Int. 2009 Mar;103(5):603-8. doi: 10.1111/j.1464-410X.2008.08118.x. Epub 2008 Nov 18.
Abstract | Full text | Related citations

Prostate-specific antigen

Adhyam M, Gupta AK.
A Review on the Clinical Utility of PSA in Cancer Prostate.
Indian J Surg Oncol. 2012 Jun;3(2):120-9. doi: 10.1007/s13193-012-0142-6. Epub 2012 Mar 3.
Abstract | Full text | Related citations

Wallner LP, Frencher SK, Hsu JW, Chao CR, Nichol MB, Loo RK, Jacobsen SJ.
Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population.
BJU Int. 2013 Jun;111(8):1245-52. doi: 10.1111/j.1464-410X.2012.11651.x. Epub 2013 Jan 15.
Abstract | Related citations

Risk stratification

So A, Goldenberg SL.
Risk stratification in prostate cancer.
Oncology Exchange, Vol. 3, No. 4, October 2004.
Abstract | Full text


Gleason score

Sfoungaristos S, Perimenis P.
Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer.
Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E93-7. doi: 10.5489/cuaj.270.
Abstract | Full text | Related citations


Menon M, Bhandari M, Gupta N, Lane Z, Peabody JO, Rogers CG, Sammon J, Siddiqui SA, Diaz M.
Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up.
Eur Urol. 2010 Dec;58(6):838-46. doi: 10.1016/j.eururo.2010.09.010. Epub 2010 Sep 17.
Abstract | Related citations


D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH.
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83.
Abstract | Full text | Related citations


Ahmed HU, Emberton M.
Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?
World J Urol. 2008 Oct;26(5):457-67. doi: 10.1007/s00345-008-0317-5. Epub 2008 Aug 14.
Abstract | Related citations

Treatment comparison

D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
Cancer. 2002 Jul 15;95(2):281-6.
Abstract | Full text | Related citations

D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A.
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
JAMA. 1998 Sep 16;280(11):969-74.
Abstract | Full text | Related citations

Gatti L, Antonelli A, Gritti A, Finamanti M, Peroni A, Simeone C.
[Short and medium term oncological results after robot-assisted prostatectomy: a comparative prospective non randomized study].
Urologia. 2013 Jul 10;80(2):135-9. doi: 10.5301/RU.2013.10834. Epub 2013 Mar 14. Italian.
Abstract | Related citations

Ludovico GM, Dachille G, Pagliarulo G, D'Elia C, Mondaini N, Gacci M, Detti B, Malossini G, Bartoletti R, Cai T.
Bilateral nerve sparing robotic-assisted radical prostatectomy is associated with faster continence recovery but not with erectile function recovery compared with retropubic open prostatectomy: the need for accurate selection of patients.
Oncol Rep. 2013 Jun;29(6):2445-50. doi: 10.3892/or.2013.2365. Epub 2013 Mar 26.
Abstract | Full text | Related citations



Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ.
20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
BJU Int. 2012 Dec;110(11):1709-13. doi: 10.1111/j.1464-410X.2012.11372.x. Epub 2012 Aug 30.
Abstract | Related citations


Abdollah F, Suardi N, Cozzarini C, Gallina A, Capitanio U, Bianchi M, Sun M, Fossati N, Passoni NM, Fiorino C, Di Muzio N, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A.
Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.
Eur Urol. 2013 Jun;63(6):998-1008. doi: 10.1016/j.eururo.2012.10.036. Epub 2012 Oct 26.
Abstract | Full text | Related citations

Alongi F, De Bari B, Franco P, Ciammella P, Chekrine T, Livi L, Jereczek-Fossa BA, Filippi AR; on behalf of AIRO Young and AIRO Prostate cancer Working Group.
The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer.
Radiol Med. 2013 Jun;118(4):660-678. Epub 2013 Jan 28.
Abstract | Related citations

Cortés-González JR, Castellanos E, Sandberg K, Eriksson MH, Wiklund P, Carlsson S, Cohn-Cedermark G, Harmenberg U, Gustafsson O, Levitt SH, Lennernäs B, Brandberg Y, Márquez M, Kälkner KM, Nilsson S.
Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
Int J Oncol. 2013 Jan;42(1):109-17. doi: 10.3892/ijo.2012.1694. Epub 2012 Nov 13.
Abstract | Related citations

Parker C, Catton C, Sydes MR.
Early salvage radiotherapy after radical prostatectomy.
J Clin Oncol. 2010 Jan 20;28(3):e45; author reply e46. doi: 10.1200/JCO.2009.24.2396. Epub 2009 Dec 14.
Abstract | Full text | Related citations

Thompson I.
Reply to C. Parker et al.
JCO Jan 20, 2010:e46; published online on December 14, 2009.
Abstract | Full text

Thompson IM, Tangen CM, Klein EA.
Is there a standard of care for pathologic stage T3 prostate cancer?
J Clin Oncol. 2009 Jun 20;27(18):2898-9. doi: 10.1200/JCO.2008.20.9460. Epub 2009 May 11.
Abstract | Full text | Related citations

Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED.
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.
J Urol. 2009 Mar;181(3):956-62. doi: 10.1016/j.juro.2008.11.032. Epub 2009 Jan 23.
Abstract | Full text | Related citations

Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K.
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
J Clin Oncol. 2009 Jun 20;27(18):2924-30. doi: 10.1200/JCO.2008.18.9563. Epub 2009 May 11.
Abstract | Full text | Related citations